[Objectives]This study was conducted to obtain porcine gastrin-releasing peptide(GRP)fusion protein.[Methods]The constructed pET32a(+)-GRP plasmid was transformed into Escherichia coli BL21(DE3)competent cells to obta...[Objectives]This study was conducted to obtain porcine gastrin-releasing peptide(GRP)fusion protein.[Methods]The constructed pET32a(+)-GRP plasmid was transformed into Escherichia coli BL21(DE3)competent cells to obtain the pET32a(+)-GRP-BL21(DE3)fusion protein expression strain,which was induced with 0.5 mM IPTG at 25℃and 150 r/min for 12 h,and the His-tagged GRP fusion protein was detected by SDS-Page gel electrophoresis and Western Blot.[Results]After optimizing the IPTG-induced expression conditions,it was confirmed that the porcine GRP fusion protein was obtained,and the porcine GRP fusion protein was soluble,stable and highly active.[Conclusions]This study lays a foundation for the subsequent preparation of anti-pig GRP antibodies.展开更多
Benign prostatic hyperplasia(BPH)is a pathologic condition of the prostate described as a substantial increase in its number of epithelial and stromal cells.BPH may significantly reduce the quality of life due to the ...Benign prostatic hyperplasia(BPH)is a pathologic condition of the prostate described as a substantial increase in its number of epithelial and stromal cells.BPH may significantly reduce the quality of life due to the initiation of bladder outlet obstruction and lower urinary tract syndromes.Current medical therapies mostly consist of inhibitors of 5α-reductase orα1-adrenergic blockers;their efficacy is often insufficient.Antagonistic analogs of neuropeptide hormones are novel candidates for the management of BPH.At first,antagonists of luteinizing hormone-releasing hormone(LHRH)have been introduced to the therapy aimed to reduce serum testosterone levels.However,they have also been found to produce an inhibitory activity on local LHRH receptors in the prostate as well as impotence and other related side effects.Since then,several preclinical and clinical studies reported the favorable effects of LHRH antagonists in BPH.In contrast,antagonists of growth hormone-releasing hormone(GHRH)and gastrin-releasing peptide(GRP)have been tested only in preclinical settings and produce significant reduction in prostate size in experimental models of BPH.They act at least in part,by blocking the action of respective ligands produced locally on prostates through their respective receptors in the prostate,and by inhibition of autocrine insulin-like growth factors-Ⅰ/Ⅱand epidermal growth factor production.GHRH and LHRH antagonists were also tested in combination resulting in a cumulative effect that was greater than that of each alone.This article will review the numerous studies that demonstrate the beneficial effects of antagonistic analogs of LHRH,GHRH and GRP in BPH,as well as suggesting a potential role for somatostatin analogs in experimental therapies.展开更多
目的:探讨血清Pro-GRP(胃泌素释放肽前体)对SCLC(小细胞肺癌)诊断的价值。方法:计算机检索Medline数据库、Cochrane图书馆、OVID、Web of Science、CNKI、万方、维普等数据库,搜索并且收集涉及血清Pro-GRP对SCLC诊断的相关文献,采用QUA...目的:探讨血清Pro-GRP(胃泌素释放肽前体)对SCLC(小细胞肺癌)诊断的价值。方法:计算机检索Medline数据库、Cochrane图书馆、OVID、Web of Science、CNKI、万方、维普等数据库,搜索并且收集涉及血清Pro-GRP对SCLC诊断的相关文献,采用QUADAS对文献的质量进行评价,采用Meta-Disc 1.4对数据进行分析。结果:按照统一的排除和纳入标准,得到符合要求的文献13篇,中文9篇,英文4篇。累计病例2587例,其中小细胞肺癌例855例,良性肺部疾病、健康、其他肿瘤共1732例。13个研究结果的汇总SEN和SPE分别为79%(76%-82%)和94%(92%-95%)。汇总+LR、-LR分别为:13.73(8.41-22.44)、0.24(0.20-0.30)。DOR为58.34(32.70-103.74),曲线下面积AUC为0.8628,Q为0.7935。结论:本研究证据显示,Pro-GRP诊断SCLC有一定的临床价值,可作为早期诊断SCLC的指标之一,但是由于纳入的研究不够多,样本量不够大,所以Pro-GRP诊断SCLC仍然需要大样本的研究加以进一步验证。展开更多
基金Supported by the Molecular Biology Program (Grant No.21407)Laboratory Medicine Center-LMC, University Hospital Linkoping, Swedenthe Development Foundation of Region Skane, Sweden
基金Supported by National Natural Science Foundation of China(31802149)China Postdoctoral Science(2019M651985)+2 种基金Natural Science Foundation of Jiangsu Province(BK20180919)Scientific Research Fund of Nanjing General Hospital of Nanjing Military Command(2016033)Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)。
文摘[Objectives]This study was conducted to obtain porcine gastrin-releasing peptide(GRP)fusion protein.[Methods]The constructed pET32a(+)-GRP plasmid was transformed into Escherichia coli BL21(DE3)competent cells to obtain the pET32a(+)-GRP-BL21(DE3)fusion protein expression strain,which was induced with 0.5 mM IPTG at 25℃and 150 r/min for 12 h,and the His-tagged GRP fusion protein was detected by SDS-Page gel electrophoresis and Western Blot.[Results]After optimizing the IPTG-induced expression conditions,it was confirmed that the porcine GRP fusion protein was obtained,and the porcine GRP fusion protein was soluble,stable and highly active.[Conclusions]This study lays a foundation for the subsequent preparation of anti-pig GRP antibodies.
基金Supported by The Medical Research Service of the Veterans Affairs Department,Departments of Pathology and Medicine,Division of Hematology/Oncology,Sylvester Comprehensive Cancer Center,University of Miami,Miller School of Medicine,the South Florida Veterans Affairs Foundation for Research and Education(all to Schally AV)the L Austin Weeks Endowment for Urologic Research(to Block NL)+2 种基金in part by a grant from the Urology Care Foundation Research Scholars Program and the American Urological Association(AUA)Southeastern Section(to Rick FG)by a stipend program of the Department of Medicine,Dresdenby the Helmholtz Alliance ICEMED(Imaging and Curing Environmental Metabolic Diseases)through the Initiative and Networking Fund of the Helmholtz Association(to Popovics P)
文摘Benign prostatic hyperplasia(BPH)is a pathologic condition of the prostate described as a substantial increase in its number of epithelial and stromal cells.BPH may significantly reduce the quality of life due to the initiation of bladder outlet obstruction and lower urinary tract syndromes.Current medical therapies mostly consist of inhibitors of 5α-reductase orα1-adrenergic blockers;their efficacy is often insufficient.Antagonistic analogs of neuropeptide hormones are novel candidates for the management of BPH.At first,antagonists of luteinizing hormone-releasing hormone(LHRH)have been introduced to the therapy aimed to reduce serum testosterone levels.However,they have also been found to produce an inhibitory activity on local LHRH receptors in the prostate as well as impotence and other related side effects.Since then,several preclinical and clinical studies reported the favorable effects of LHRH antagonists in BPH.In contrast,antagonists of growth hormone-releasing hormone(GHRH)and gastrin-releasing peptide(GRP)have been tested only in preclinical settings and produce significant reduction in prostate size in experimental models of BPH.They act at least in part,by blocking the action of respective ligands produced locally on prostates through their respective receptors in the prostate,and by inhibition of autocrine insulin-like growth factors-Ⅰ/Ⅱand epidermal growth factor production.GHRH and LHRH antagonists were also tested in combination resulting in a cumulative effect that was greater than that of each alone.This article will review the numerous studies that demonstrate the beneficial effects of antagonistic analogs of LHRH,GHRH and GRP in BPH,as well as suggesting a potential role for somatostatin analogs in experimental therapies.
文摘目的:探讨血清Pro-GRP(胃泌素释放肽前体)对SCLC(小细胞肺癌)诊断的价值。方法:计算机检索Medline数据库、Cochrane图书馆、OVID、Web of Science、CNKI、万方、维普等数据库,搜索并且收集涉及血清Pro-GRP对SCLC诊断的相关文献,采用QUADAS对文献的质量进行评价,采用Meta-Disc 1.4对数据进行分析。结果:按照统一的排除和纳入标准,得到符合要求的文献13篇,中文9篇,英文4篇。累计病例2587例,其中小细胞肺癌例855例,良性肺部疾病、健康、其他肿瘤共1732例。13个研究结果的汇总SEN和SPE分别为79%(76%-82%)和94%(92%-95%)。汇总+LR、-LR分别为:13.73(8.41-22.44)、0.24(0.20-0.30)。DOR为58.34(32.70-103.74),曲线下面积AUC为0.8628,Q为0.7935。结论:本研究证据显示,Pro-GRP诊断SCLC有一定的临床价值,可作为早期诊断SCLC的指标之一,但是由于纳入的研究不够多,样本量不够大,所以Pro-GRP诊断SCLC仍然需要大样本的研究加以进一步验证。
